Clinical Trial Update: ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

This entry describes a Phase 2 trial evaluating whether circulating tumor DNA can predict response to chemo-immunotherapy and detect minimal residual disease in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: University of Miami | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: RECRUITING